Ornidazol en el tratamiento de la amibiasis intestinal
Abstract
Para conocer la actividad terapéutica del Omidazol (Tiberal) en la amibiasis intestinal, se administró el producto en 40 pacientes divididos en dos grupos (1 y II) de 26 y 14 casos a la dosis de 500 mgm. Cada 12 horas por 7y 5 días respectivamente. Siete días después de finalizado el tratamiento se practicó control coproparasitoscópico mediante examen directo y por concentración. El control se logró practicar en 20 pacientes del grupo 1 y en 11 del grupo II con porcentajes de curación de 85.0 y 90.90% respectivamente; en total en ambos grupos hubo curación parasitológica en el 87.0%. Se comparan los resultados con los reportados por otros autores y se concluye que en efecto el Omidazol es un imidaólico útil en el tratamiento de la Amibiasis intestinal.
Copyright (c) 2012 Ricardo Soto Urribarrí
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Kasmera journal is registered under a Creative Commons an Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0), available at: https://creativecommons.org/licenses/by-nc-sa/4.0/deed.en; which guarantees the freedom to share-copy and redistribute the material in any medium or format and adapt-remix, transform and build from the material, provided that the name of the authors, the Department of Infectious and Tropical Diseases, Zulia´s University and Kasmera Journal, you must also provide a link to the original document and indicate if changes have been made.
The Department of Infectious and Tropical Diseases, University of Zulia and Kasmera Journal do not retain the rights to published manuscript and the contents are the sole responsibility of the authors, who retain their moral, intellectual, privacy and publicity rights. The guarantee on the intervention of the manuscript (revision, correction of style, translation, layout) and its subsequent dissemination is granted through a license of use and not through a transfer of rights, which represents the Kasmera Journal and Department Infectious Diseases, University of Zulia are exempt from any liability that may arise from ethical misconduct by the authors.
Kasmera is considered a green SHERPA/RoMEO journal, that is, it allows self-archiving of both the pre-print (draft of a manuscript) and the post-print (the corrected and peer-reviewed version) and even the final version (layout as it will be published in the journal) both in personal repositories and in institutional and databases.
_pequeño1.png)
_pequeña.png)
_pequeña.png)
_pequeña.jpg)
